Symbols / KPRX
KPRX Chart
About
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.39M |
| Enterprise Value | -11.60M | Income | -8.54M | Sales | — |
| Book/sh | 6.53 | Cash/sh | 5.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.90 | PEG | — |
| P/S | inf | P/B | 0.31 | P/C | — |
| EV/EBITDA | 1.25 | EV/Sales | — | Quick Ratio | 8.54 |
| Current Ratio | 8.79 | Debt/Eq | 1.80 | LT Debt/Eq | — |
| EPS (ttm) | -2.19 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-07 06:00 | ROA | -17.07% |
| ROE | -32.58% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.68M |
| Shs Float | 3.56M | Short Float | 0.38% | Short Ratio | 0.21 |
| Short Interest | — | 52W High | 4.18 | 52W Low | 1.76 |
| Beta | -0.81 | Avg Volume | 51.00K | Volume | 13.52K |
| Target Price | $12.00 | Recom | Buy | Prev Close | $1.96 |
| Price | $2.01 | Change | 2.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.00
Mean price target
2. Current target
$2.01
Latest analyst target
3. DCF / Fair value
$-32.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.01
Low
$12.00
High
$12.00
Mean
$12.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-23 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-02-09 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-24 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-14 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-09 | main | Maxim Group | Buy → Buy | $2 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-24 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2023-02-09 | up | Maxim Group | Hold → Buy | $12 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-02-08 | reit | Ladenburg Thalmann | — → Buy | $119 |
- Kiora Pharma (NASDAQ: KPRX) wins US patent amid Phase 2 KIO-104 eye study - Stock Titan Mon, 01 Dec 2025 08
- KPRX Forecast — Price Prediction for 2026. Should I Buy KPRX? - Intellectia AI Sat, 31 May 2025 12
- Momentum Shift: Can KPRX stock double in the next year - 2025 Price Momentum & Fast Gain Stock Tips - baoquankhu1.vn Sat, 21 Feb 2026 14
- Is KPRX a potential multi bagger - 2025 Dividend Review & Fast Gain Stock Trading Tips - mfd.ru Sat, 21 Feb 2026 03
- Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan ue, 27 Jan 2026 08
- symbol__ Stock Quote Price and Forecast - CNN Mon, 12 Feb 2024 02
- Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS Sat, 07 Feb 2026 08
- KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView hu, 20 Jun 2024 07
- We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance Fri, 15 Nov 2024 08
- Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2026 - MarketBeat Sat, 11 May 2024 13
- Kiora Pharmaceuticals (KPRX) - Zacks Investment Research ue, 09 Nov 2021 11
- Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? - InvestorPlace hu, 01 Feb 2024 08
- Does KPRX have declining or rising EPS - Market Movers & Weekly High Return Forecasts - mfd.ru Mon, 16 Feb 2026 06
- Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PR Newswire hu, 30 Oct 2025 07
- Karyopharm Therapeutics: Speculative Biotech Stock Caught Between Deep Losses And Quiet Hope - AD HOC NEWS Sun, 18 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15941 | — | — | Stock Award(Grant) at price 0.00 per share. | STREM BRIAN M. | Chief Executive Officer | — | 2025-04-01 00:00:00 | D |
| 1 | 7772 | — | — | Stock Award(Grant) at price 0.00 per share. | DANIELS ERIC JOSEPH | Officer | — | 2025-04-01 00:00:00 | D |
| 2 | 7772 | — | — | Stock Award(Grant) at price 0.00 per share. | TOSCA MELISSA | Chief Financial Officer | — | 2025-04-01 00:00:00 | D |
| 3 | 1250 | 4600 | — | Purchase at price 3.68 per share. | STENGONE CARMINE N | Director | — | 2024-09-11 00:00:00 | D |
| 4 | 3000 | 10800 | — | Purchase at price 3.60 per share. | SHAPIRO ARON | Director | — | 2024-09-10 00:00:00 | I |
| 5 | 5000 | 19800 | — | Purchase at price 3.96 per share. | TYLE PRAVEEN | Director | — | 2024-08-19 00:00:00 | D |
| 6 | 1250 | 4825 | — | Purchase at price 3.86 per share. | WALTERS-HOFFERT LISA | Director | — | 2024-08-19 00:00:00 | D |
| 7 | 2000 | 6420 | — | Purchase at price 3.21 per share. | TOSCA MELISSA | Chief Financial Officer | — | 2024-08-14 00:00:00 | D |
| 8 | 15629 | — | — | Stock Award(Grant) at price 0.00 per share. | STREM BRIAN M. | Chief Executive Officer | — | 2024-07-01 00:00:00 | D |
| 9 | 7355 | — | — | Stock Award(Grant) at price 0.00 per share. | DANIELS ERIC JOSEPH | Officer | — | 2024-07-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -427.34K | -824.27K | -57.10K | -45.31K |
| TaxRateForCalcs | 0.36 | 0.21 | 0.03 | 0.01 |
| NormalizedEBITDA | 6.88M | -8.44M | -11.64M | -10.63M |
| TotalUnusualItems | -1.18M | -3.93M | -2.00M | -3.28M |
| TotalUnusualItemsExcludingGoodwill | -1.18M | -3.93M | -2.00M | -3.28M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 3.59M | -12.51M | -13.58M | -13.77M |
| ReconciledDepreciation | 19.20K | 51.80K | 41.61K | 45.30K |
| EBITDA | 5.70M | -12.36M | -13.65M | -13.91M |
| EBIT | 5.68M | -12.41M | -13.69M | -13.96M |
| NetInterestIncome | 1.23M | 162.86K | 48.29K | -5.71K |
| InterestExpense | 21.45K | 11.13K | 8.60K | 6.85K |
| InterestIncome | 1.25M | 173.99K | 56.89K | 1.14K |
| NormalizedIncome | 4.35M | -9.41M | -11.64M | -10.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 3.59M | -12.51M | -13.58M | -13.77M |
| TotalExpenses | 10.42M | 8.69M | 11.73M | 10.67M |
| TotalOperatingIncomeAsReported | 4.51M | -12.59M | -12.31M | -14.24M |
| DilutedAverageShares | 4.13M | 538.01K | 81.37K | 26.79K |
| BasicAverageShares | 3.87M | 538.01K | 81.37K | 26.79K |
| DilutedEPS | 0.87 | -24.25 | -166.95 | -514.08 |
| BasicEPS | 0.93 | -24.25 | -166.95 | -514.08 |
| DilutedNIAvailtoComStockholders | 3.59M | -13.04M | -13.58M | -13.77M |
| NetIncomeCommonStockholders | 3.59M | -13.04M | -13.58M | -13.77M |
| OtherunderPreferredStockDividend | 0.00 | 530.99K | 0.00 | |
| NetIncome | 3.59M | -12.51M | -13.58M | -13.77M |
| NetIncomeIncludingNoncontrollingInterests | 3.59M | -12.51M | -13.58M | -13.77M |
| NetIncomeContinuousOperations | 3.59M | -12.51M | -13.58M | -13.77M |
| TaxProvision | 2.07M | 90.32K | -113.01K | -192.60K |
| PretaxIncome | 5.66M | -12.42M | -13.70M | -13.96M |
| OtherIncomeExpense | -1.15M | -3.90M | -2.02M | -3.28M |
| OtherNonOperatingIncomeExpenses | 26.07K | 28.84K | -14.50K | |
| SpecialIncomeCharges | -1.18M | -3.93M | -578.39K | -3.28M |
| GainOnSaleOfPPE | -3.86K | -28.38K | 4.21K | 0.00 |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | -278.19K | |||
| WriteOff | 2.01M | 1.90M | 0.00 | |
| ImpairmentOfCapitalAssets | 104.17K | 0.00 | 4.04M | |
| RestructuringAndMergernAcquisition | -937.47K | 1.99M | 582.61K | -475.96K |
| GainOnSaleOfSecurity | -1.43M | |||
| NetNonOperatingInterestIncomeExpense | 1.23M | 162.86K | 48.29K | -5.71K |
| InterestExpenseNonOperating | 21.45K | 11.13K | 8.60K | 6.85K |
| InterestIncomeNonOperating | 1.25M | 173.99K | 56.89K | 1.14K |
| OperatingIncome | 5.58M | -8.69M | -11.73M | -10.67M |
| OperatingExpense | 10.42M | 8.69M | 11.73M | 10.67M |
| OtherOperatingExpenses | -20.00K | |||
| ResearchAndDevelopment | 4.90M | 4.03M | 3.45M | 5.35M |
| SellingGeneralAndAdministration | 5.54M | 4.66M | 8.28M | 5.32M |
| GeneralAndAdministrativeExpense | 5.54M | 4.66M | 8.28M | 5.32M |
| OtherGandA | 5.54M | 4.66M | 8.28M | 5.32M |
| TotalRevenue | 16.00M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 16.00M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.00M | 856.18K | 199.61K | 35.18K |
| ShareIssued | 3.00M | 856.18K | 199.61K | 35.18K |
| TotalDebt | 57.17K | 106.89K | 105.78K | 209.41K |
| TangibleBookValue | 19.07M | -2.70M | 664.44K | 3.81M |
| InvestedCapital | 25.76M | 6.11M | 11.41M | 14.58M |
| WorkingCapital | 23.70M | 3.10M | 4.41M | 7.38M |
| NetTangibleAssets | 19.07M | -2.70M | 664.44K | 3.81M |
| CapitalLeaseObligations | 57.17K | 106.89K | 105.78K | 209.41K |
| CommonStockEquity | 25.76M | 6.11M | 11.41M | 14.58M |
| PreferredStockEquity | 4.00 | 4.00 | ||
| TotalCapitalization | 25.76M | 6.11M | 11.41M | 14.58M |
| TotalEquityGrossMinorityInterest | 25.76M | 6.11M | 11.41M | 14.58M |
| StockholdersEquity | 25.76M | 6.11M | 11.41M | 14.58M |
| GainsLossesNotAffectingRetainedEarnings | -282.16K | -182.80K | -182.74K | -86.43K |
| OtherEquityAdjustments | -282.16K | -182.80K | -182.74K | -86.43K |
| RetainedEarnings | -143.38M | -146.98M | -134.46M | -120.88M |
| AdditionalPaidInCapital | 169.16M | 153.19M | 146.04M | 135.54M |
| CapitalStock | 267.68K | 77.08K | 17.99K | 3.17K |
| CommonStock | 267.68K | 77.08K | 17.99K | 3.17K |
| PreferredStock | 4.00 | 4.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 10.72M | 7.60M | 7.27M | 5.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.72M | 5.97M | 4.00M | 3.94M |
| OtherNonCurrentLiabilities | 4.19M | 5.13M | 3.31M | 3.05M |
| NonCurrentDeferredLiabilities | 490.69K | 779.44K | 689.12K | 802.13K |
| NonCurrentDeferredTaxesLiabilities | 490.69K | 779.44K | 689.12K | 802.13K |
| LongTermDebtAndCapitalLeaseObligation | 33.81K | 59.82K | 0.00 | 90.57K |
| LongTermCapitalLeaseObligation | 33.81K | 59.82K | 0.00 | 90.57K |
| CurrentLiabilities | 6.01M | 1.63M | 3.27M | 1.61M |
| OtherCurrentLiabilities | 322.38K | |||
| CurrentDebtAndCapitalLeaseObligation | 23.36K | 47.07K | 105.78K | 118.85K |
| CurrentCapitalLeaseObligation | 23.36K | 47.07K | 105.78K | 118.85K |
| PayablesAndAccruedExpenses | 5.99M | 1.59M | 2.84M | 1.49M |
| CurrentAccruedExpenses | 3.24M | 1.38M | 1.84M | 1.33M |
| Payables | 2.74M | 206.26K | 1.01M | 160.62K |
| TotalTaxPayable | 2.33M | 0.00 | ||
| IncomeTaxPayable | 2.33M | 0.00 | ||
| AccountsPayable | 415.59K | 206.26K | 1.01M | 160.62K |
| TotalAssets | 36.48M | 13.71M | 18.68M | 20.13M |
| TotalNonCurrentAssets | 6.78M | 8.97M | 11.00M | 11.14M |
| OtherNonCurrentAssets | 28.97K | 45.03K | 82.26K | 87.96K |
| GoodwillAndOtherIntangibleAssets | 6.69M | 8.81M | 10.74M | 10.77M |
| OtherIntangibleAssets | 6.69M | 8.81M | 10.74M | 10.77M |
| Goodwill | 0.00 | |||
| NetPPE | 62.40K | 114.95K | 172.17K | 283.41K |
| AccumulatedDepreciation | -1.02K | -6.29K | -117.32K | -113.13K |
| GrossPPE | 63.43K | 121.24K | 289.49K | 396.54K |
| Leases | 0.00 | 22.57K | 22.57K | |
| OtherProperties | 57.17K | 118.72K | 205.39K | 297.81K |
| MachineryFurnitureEquipment | 6.26K | 2.52K | 61.53K | 76.16K |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 29.71M | 4.74M | 7.68M | 8.99M |
| OtherCurrentAssets | 2.04M | 233.38K | 343.07K | 606.52K |
| PrepaidAssets | 606.52K | |||
| Receivables | 871.44K | 2.05M | 1.37M | 529.56K |
| OtherReceivables | 601.20K | 529.56K | ||
| TaxesReceivable | 270.25K | 2.05M | 1.37M | 529.56K |
| CashCashEquivalentsAndShortTermInvestments | 26.79M | 2.45M | 5.96M | 7.85M |
| OtherShortTermInvestments | 23.00M | 0.00 | ||
| CashAndCashEquivalents | 3.79M | 2.45M | 5.96M | 7.85M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 8.55M | -9.56M | -10.43M | -10.74M |
| RepurchaseOfCapitalStock | 0.00 | -15.63K | 0.00 | |
| RepaymentOfDebt | 0.00 | -212.28K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 15.00M | 6.97M | 5.38M | 17.75M |
| CapitalExpenditure | -6.26K | -63.87K | ||
| EndCashPosition | 3.80M | 2.46M | 6.01M | 7.90M |
| BeginningCashPosition | 2.46M | 6.01M | 7.90M | 1.23M |
| EffectOfExchangeRateChanges | -57.23K | 36.02K | -85.04K | -81.50K |
| ChangesInCash | 1.39M | -3.59M | -1.80M | 6.75M |
| FinancingCashFlow | 15.50M | 5.97M | 8.62M | 17.58M |
| CashFlowFromContinuingFinancingActivities | 15.50M | 5.97M | 8.62M | 17.58M |
| NetOtherFinancingCharges | -1.19M | -1.31M | -1.00M | |
| ProceedsFromStockOptionExercised | 1.69M | 307.08K | 3.26M | 50.00K |
| NetCommonStockIssuance | 15.00M | 6.97M | 5.36M | 17.75M |
| CommonStockPayments | 0.00 | -15.63K | 0.00 | |
| CommonStockIssuance | 15.00M | 6.97M | 5.38M | 17.75M |
| NetIssuancePaymentsOfDebt | 0.00 | -212.28K | ||
| NetLongTermDebtIssuance | 0.00 | -212.28K | ||
| LongTermDebtPayments | 0.00 | -212.28K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -22.66M | 0.00 | 6.38K | -157.02K |
| CashFlowFromContinuingInvestingActivities | -22.66M | 0.00 | 6.38K | -157.02K |
| NetInvestmentPurchaseAndSale | -22.66M | 0.00 | ||
| SaleOfInvestment | 12.98M | 0.00 | ||
| PurchaseOfInvestment | -35.63M | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | -93.16K | ||
| PurchaseOfBusiness | 0.00 | -93.16K | ||
| NetPPEPurchaseAndSale | -6.26K | 0.00 | 6.38K | -63.87K |
| SaleOfPPE | 0.00 | 6.38K | 0.00 | |
| PurchaseOfPPE | -6.26K | 0.00 | 0.00 | -63.87K |
| OperatingCashFlow | 8.56M | -9.56M | -10.43M | -10.68M |
| CashFlowFromContinuingOperatingActivities | 8.56M | -9.56M | -10.43M | -10.68M |
| ChangeInWorkingCapital | 3.67M | -1.82M | 668.51K | -1.04M |
| ChangeInOtherCurrentLiabilities | -46.50K | 584.00 | -103.63K | -181.98K |
| ChangeInOtherCurrentAssets | 15.23K | -7.58K | -22.46K | 14.11K |
| ChangeInPayablesAndAccruedExpense | 4.49M | -1.27M | 1.39M | -269.78K |
| ChangeInAccruedExpense | 4.26M | -459.71K | 609.72K | 40.88K |
| ChangeInPayable | 226.12K | -808.02K | 782.46K | -310.67K |
| ChangeInAccountPayable | 226.12K | -808.02K | 782.46K | -310.67K |
| ChangeInPrepaidAssets | -1.82M | 885.00 | 275.16K | -156.95K |
| ChangeInReceivables | 1.03M | -548.11K | -872.74K | -441.20K |
| OtherNonCashItems | -916.78K | 2.00M | 675.02K | -323.70K |
| StockBasedCompensation | 656.59K | 754.94K | 462.45K | 842.48K |
| UnrealizedGainLossOnInvestmentSecurities | 119.00 | 0.00 | ||
| AssetImpairmentCharge | 2.11M | 1.90M | 0.00 | 4.04M |
| AmortizationOfSecurities | -283.47K | 0.00 | ||
| DeferredTax | -288.75K | 90.32K | -113.01K | -192.60K |
| DeferredIncomeTax | -288.75K | 90.32K | -113.01K | -192.60K |
| DepreciationAmortizationDepletion | 19.20K | 51.80K | 41.61K | 45.30K |
| DepreciationAndAmortization | 19.20K | 51.80K | 41.61K | 45.30K |
| AmortizationCashFlow | 19.20K | 51.80K | 25.00K | |
| AmortizationOfIntangibles | 19.20K | 51.80K | 25.00K | |
| Depreciation | 20.30K | |||
| OperatingGainsLosses | -759.00 | -25.50K | 1.42M | -278.19K |
| GainLossOnInvestmentSecurities | -4.52K | 1.43M | ||
| GainLossOnSaleOfPPE | 3.76K | 28.38K | -4.21K | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | -53.88K | 0.00 | |
| NetIncomeFromContinuingOperations | 3.59M | -12.51M | -13.58M | -13.77M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KPRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|